Agilent Announces Applications Open for LabCentral Golden Ticket
November 21 2019 - 8:00AM
Business Wire
Sponsorship will enable a promising biotech startup to advance
scientific discovery
Agilent Technologies Inc. (NYSE: A) has announced that the
nomination process to submit proposals to receive an
Agilent-sponsored LabCentral Golden Ticket is open for interested
life sciences and biotech startup companies. LabCentral, based in
Cambridge, Massachusetts, is an independent, shared laboratory
space designed as a launchpad for high-potential life sciences and
biotech startups.
Agilent as a platinum sponsor at LabCentral has equipped the
facility’s shared laboratory workspace with a variety of Agilent
technologies, including a high-resolution mass spectrometry system,
and a cell analysis extracellular flux (XF) analyzer, amongst other
instruments. This will be the second Golden Ticket presented to an
innovative life-sciences startup company. This award underwrites
the cost of one lab bench for one year, including the benefit of
LabCentral's shared infrastructure and services.
The first Agilent-sponsored Golden Ticket was awarded in January
2018 to Angiex, a developer of vascular-targeted biotherapeutics.
Angiex targets fundamental aspects of endothelial biology with a
focus on angiogenesis. Angiex’s lead product is an antibody-drug
conjugate (ADC) therapy for cancer, which effectively regresses
highly malignant tumors in mice, and has the potential to treat
cancers such as pancreatic, lung, and liver cancers and
glioblastoma multiforme.
“Agilent is excited to be part of LabCentral and offer this
second Golden Ticket award in this tremendous biotech community,”
said Darlene Solomon, senior vice president, and chief technology
officer for Agilent. “We are very proud to offer our technologies
to LabCentral residents and our support for emerging pharma and
biotech companies to help accelerate innovation in critical areas
that can improve human health.”
Agilent is accepting online applications for the Golden Ticket
Contest until February 14, 2020 (11:59 p.m. PST). The finalists
will present to an esteemed review panel at a public event at
LabCentral. To learn more or apply, visit
www.agilent.com/en/promotions/goldenticket.
LabCentral offers a supportive and nurturing environment
designed to inspire interaction and collaboration. Startups work
side-by-side on some of the most exciting potential breakthroughs
in diagnostics and therapeutics, and prevention—across the spectrum
of diseases. Biopharma is a fast-growing market for Agilent, and
Cambridge, MA is a well-known hub of innovation in this field.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. With more than
50 years of insight and innovation, Agilent instruments, software,
services, solutions, and people provide trusted answers to
customers' most challenging questions. The company generated
revenues of $4.91 billion in fiscal 2018 and employs 15,500 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, subscribe to
our Newsroom. Follow Agilent on LinkedIn, Twitter, and
Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191121005147/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Sep 2023 to Sep 2024